AstraZeneca Plc (AZN) is doubling down on biologics in a big way, announcing a major expansion of its partnership with Hong Kong-based drug discovery firm Harbour BioMed while simultaneously committing $2 billion to beef up its U.S. manufacturing capabilities.

Harbour BioMed revealed Sunday that it's advancing its global strategic collaboration with AstraZeneca, originally kicked off in March 2025. The extended partnership focuses on discovering and developing next-generation biotherapeutics, specifically antibody-drug conjugates and T cell engagers for immunology and oncology applications.

Here's how the arrangement works: Over the next four years, AstraZeneca will continue nominating discovery programs to Harbour BioMed annually, then retain the option to license those programs for further development. It's essentially a structured pipeline deal that gives AstraZeneca first dibs on promising candidates emerging from Harbour BioMed's research efforts.

The financial terms remain consistent with the March framework. Harbour BioMed can earn option and exercise fees, development and commercial milestone payments, plus tiered royalties on future net sales of licensed programs. The initial collaboration structure includes an upfront payment, near-term milestone payments, and option exercise fees totaling $175 million, with the potential for up to $4.4 billion in additional development and commercial milestone payments down the line.

AstraZeneca is also putting skin in the game through a $105 million equity investment, acquiring 9.15% of newly issued Harbour BioMed shares. The partnership leverages Harbour BioMed's proprietary Harbour Mice fully human antibody technology platform across multiple therapeutic areas.

Both parties have the option to add additional programs over the next five years, with the possibility of extending the agreement for another five years if both sides agree. It's the kind of flexible framework that pharmaceutical companies love because it allows them to scale up or down based on what's actually working in the lab.

Massive Manufacturing Investment in Maryland

On Friday, AstraZeneca unveiled plans to invest $2 billion expanding its Maryland manufacturing footprint, a move that signals serious confidence in its biologics pipeline. The investment includes a significant expansion of the company's flagship biologics manufacturing facility in Frederick and construction of a brand new state-of-the-art facility in Gaithersburg dedicated to developing and producing innovative molecules for clinical trials.

The numbers are substantial: The investment will support 2,600 jobs across both sites, including retained local roles, construction activity, and 300 newly created highly skilled positions. That's real economic impact in a sector that pays well above average wages.

The Frederick facility currently produces biologics, but the planned expansion will nearly double its commercial manufacturing capacity. This increased output will support existing medicines and, for the first time, enable production across AstraZeneca's rare disease portfolio. The expansion will create 200 highly skilled jobs and 900 construction roles, with operations expected to begin in 2029.

Meanwhile, the new Gaithersburg clinical manufacturing facility will expand AstraZeneca's existing footprint in the area. This site will focus on the clinical supply side of the business, producing the experimental drug candidates needed for clinical trials. The facility will be fully operational by 2029, creating an additional 100 permanent jobs while retaining 400 existing roles and supporting 1,000 construction-related positions.

Why Maryland? The state has become a biologics manufacturing hub, and AstraZeneca has maintained a presence there for years. The expansion builds on existing infrastructure and talent pools while positioning the company to meet growing demand for complex biologics and rare disease treatments.

AstraZeneca stock traded up 0.26% at $91.24 on Monday following the announcements.